NASDAQ:PCSA Processa Pharmaceuticals (PCSA) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free PCSA Stock Alerts $1.60 +0.07 (+4.58%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$1.54▼$1.6250-Day Range$1.52▼$2.9952-Week Range$1.40▼$18.00Volume24,715 shsAverage Volume1.35 million shsMarket Capitalization$4.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Processa Pharmaceuticals alerts: Email Address Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Processa Pharmaceuticals Stock (NASDAQ:PCSA)Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.Read More PCSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCSA Stock News HeadlinesApril 11, 2024 | msn.comU.S. shares lower at close of trade; Dow Jones Industrial Average down 1.09%April 11, 2024 | finance.yahoo.comProcessa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b TrialApril 24, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”April 7, 2024 | finance.yahoo.comInsider Buyers At Processa Pharmaceuticals Recover Some Losses, But Still Down US$40kMarch 28, 2024 | nz.finance.yahoo.comEva Mendes says she had 'non-verbal agreement' with Ryan Gosling to be a stay-at-home momMarch 28, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 25, 2024 | globenewswire.comProcessa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual MeetingFebruary 24, 2024 | msn.comProcessa Pharmaceuticals (PCSA) Price Target Increased by 1900.00% to 81.60April 24, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.February 21, 2024 | finance.yahoo.comProcessa Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 21, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 14, 2024 | finance.yahoo.comProcessa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual ConferenceFebruary 14, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual ConferenceFebruary 6, 2024 | markets.businessinsider.comProcessa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleFebruary 6, 2024 | investing.comProcessa Pharmaceuticals Inc (PCSA)February 1, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Closing of $7.0 Million Public OfferingFebruary 1, 2024 | msn.comProcessa Pharmaceuticals Announces Offering Pricing DetailsJanuary 27, 2024 | marketwatch.comProcessa Pharmaceuticals Shares Drop 24% After Pricing OfferingJanuary 26, 2024 | msn.comProcessa Pharmaceuticals prices discounted stock and warrants offering to raise $7MJanuary 26, 2024 | msn.comWhat's Going On With Anti Cancer Focused Processa Pharmaceuticals Stock Today?January 26, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Pricing of $7.0 Million Public OfferingJanuary 25, 2024 | marketwatch.comProcessa Pharmaceuticals Shares More Than Double After Completing Safety Evaluation of Cancer TreatmentJanuary 25, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 DosesJanuary 20, 2024 | msn.comProcessa Pharmaceuticals Expands NGC-Cap Cancer ProgramJanuary 19, 2024 | finanznachrichten.deProcessa Pharmaceuticals, Inc.: Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast CancerJanuary 19, 2024 | msn.comWhy Processa Pharmaceuticals (PCSA) Stock Is SkyrocketingJanuary 19, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast CancerSee More Headlines Receive PCSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Processa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today4/23/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PCSA CUSIPN/A CIK1533743 Webwww.processapharmaceuticals.com Phone(443) 776-3133Fax443-288-4420Employees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($7.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-141.42% Return on Assets-122.25% Debt Debt-to-Equity RatioN/A Current Ratio7.70 Quick Ratio7.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.05 per share Price / Book0.40Miscellaneous Outstanding Shares2,860,000Free Float2,222,000Market Cap$4.58 million OptionableNot Optionable Beta0.53 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. George K. Ng Esq. (Age 50)J.D., Chief Executive Officer Comp: $400.27kDr. David Young Ph.D. (Age 71)Pharm.D., Co-Founder, President of Research and Development & Director Comp: $160.2kDr. Sian E. Bigora Ph.D. (Age 64)Pharm.D., Co-Founder and Chief Development & Regulatory Officer Comp: $184.87kMr. James H. Stanker (Age 66)Chief Financial Officer Comp: $160.2kMr. Patrick Lin (Age 59)Co-Founder, Chief Business & Strategy Officer Comp: $117.15kMs. Wendy J. Guy (Age 60)Co-Founder, Chief Administrative Officer & Corporate Secretary Comp: $94.19kMore ExecutivesKey CompetitorsLongeveronNASDAQ:LGVNChina PharmaNYSE:CPHIExicureNASDAQ:XCURSeelos TherapeuticsNASDAQ:SEELPetros PharmaceuticalsNASDAQ:PTPIView All CompetitorsInsiders & InstitutionsDavid YoungBought 21,000 shares on 2/7/2024Total: $51,450.00 ($2.45/share)Spinnaker TrustBought 76,865 shares on 2/2/2024Ownership: 6.249%Patrick LinBought 2,500 shares on 1/31/2024Total: $5,925.00 ($2.37/share)Justin W YorkeBought 8,000 shares on 1/30/2024Total: $21,520.00 ($2.69/share)George K NgBought 10,000 shares on 1/30/2024Total: $27,000.00 ($2.70/share)View All Insider TransactionsView All Institutional Transactions PCSA Stock Analysis - Frequently Asked Questions Should I buy or sell Processa Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Processa Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PCSA shares. View PCSA analyst ratings or view top-rated stocks. How have PCSA shares performed in 2024? Processa Pharmaceuticals' stock was trading at $6.6920 on January 1st, 2024. Since then, PCSA stock has decreased by 76.1% and is now trading at $1.60. View the best growth stocks for 2024 here. When is Processa Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PCSA earnings forecast. How were Processa Pharmaceuticals' earnings last quarter? Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced its quarterly earnings results on Friday, November, 12th. The company reported ($3.80) earnings per share for the quarter, missing analysts' consensus estimates of ($3.60) by $0.20. During the same quarter last year, the firm earned ($11.00) EPS. When did Processa Pharmaceuticals' stock split? Processa Pharmaceuticals's stock reverse split on Monday, January 22nd 2024. The 1-20 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Processa Pharmaceuticals? Shares of PCSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PCSA) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Processa Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
